News & Updates

Supplementation with vitamin B may or may not reduce the risk of certain cancers, with varying effects depending on the type of cancer and vitamin B compounds, according to a study.

In the treatment of patients with interstitial lung disease (ILD) and early-stage non–small cell lung cancer (NSCLC), stereotactic ablative radiotherapy (SABR) has met the prespecified acceptability thresholds for both toxicity and efficacy, according to the single-arm, phase II ASPIRE-ILD study.

Patients with differentiated thyroid cancer (DTC) may experience a significant decline in health-related quality of life (HR-QoL) 3 months after thyroidectomy, but their HR-QoL will gradually improve and even exceed preoperative QoL by year 5, suggests a study.

After 29 months of minimum follow‐up, nivolumab plus chemotherapy and nivolumab plus ipilimumab continued to demonstrate clinically meaningful overall survival (OS) benefit vs chemotherapy in patients with previously untreated, unresectable, advanced, recurrent, or metastatic oesophageal squamous-cell carcinoma (ESCC), according to results of the global, open-label, phase III CheckMate 648 trial.

Bariatric surgery appears to have a protective effect on the risk of breast cancer in women with obesity, especially those with hyperinsulinemia, according to data from the Swedish Obese Subjects (SOS) study.

Individuals who regularly eat ultra-processed foods are at greater risk of death, which is driven by causes other than cancer and cardiovascular diseases (CVD), reports a study.

In the second-line treatment of patients with metastatic colorectal cancer harbouring KRAS mutation, onvansertib combined with FOLIFRI/bevacizumab demonstrates promising clinical activity while having a manageable safety profile, according to the results of a phase Ib study.